Skip to main content
OpenTrials
Completed

NCT Number: NCT04627103

Procedure for Duodenal-Ileal Diversion With a Sleeve Gastrectomy for Patients With Obesity and Type 2 Diabetes Mellitus

Study will monitor weight loss and metabolic indicators for subjects in multi-center, single arm trial.

Completed

Looking for future studies?

Notify Me

Key information

Age range

19 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

QEII Health Sciences Centre, Halifax, Nova Scotia, Canada

Loading trial locations.

About this study

Multi-Center, Open-label Pilot Study to Evaluate the Safety and Effectiveness of the GI Windows Single Neodymium Magnet Anastomosis Procedure When Used to Create a Duodenal-Ileal Diversion with a Sleeve Gastrectomy (SNAP-S) for Subjects with Obesity and Type 2 Diabetes Mellitus (T2DM)

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 19-65 years at screening
  • Body mass index (BMI) ≥35 and ≤50
  • T2DM diagnosis ≥6 months but < 10 years, with 1 or more oral diabetes medications, HbA1c ≥ 6.5% but < 10.0% at time of enrollment.
  • HbA1c must be stable over a 3-month period.
  • Weight stable over 3-month period
  • Obesity-related comorbidities (hypertension, dyslipidemia, sleep apnea) must be well-controlled
  • Agrees to refrain from any type of additional bariatric or reconstructive surgery that would affect body weight for a duration of 2 years
  • If female, subject must commit to not becoming pregnant for 24 months and agree to use contraception during this period
  • Able to understand and sign informed consent documents.

Exclusion criteria

  • Known or suspected allergy to nickel or titanium or nitinol
  • Type 1 diabetes or poorly controlled type 2 diabetes
  • Use of injectable insulin
  • Any documented conditions for which endoscopy would be contraindicated
  • Contraindication to general anesthesia
  • History of chronic gastrointestinal disease
  • Congenial or acquired anomalies of the GI tract
  • Any previous major surgery on the stomach, duodenum, hepatobiliary tree (excluding gallbladder), pancreas, or right colon.
  • Uncontrolled hypertension
  • Pre-existing severe comorbid cardio-respiratory disease
  • History of chronic gastrointestinal disease
  • Specific genetic or hormonal cause of obesity
  • Recent tobacco/nicotine product cessation (within 3 months prior)

Treatment and study plan

Self Forming Magnetic (SFM) Anastomosis System

Device

The SFM will be placed using an endoscope in the duodenum and laparoscopically into the ileum. A compression anastomosis will be created in each of the subjects and the diversion of enteral flow from the duodenum to ileum will create a metabolic effect that will induce weight loss and impact Type 2 Diabetes. Following the diversion being created, a gastric sleeve will be created according to standard technique.

Primary outcomes

  1. Weight Loss

    Time frame: 12 months

    Weight loss measured as a percent of total body weight (TBW)

Secondary outcomes

  1. Percent Responders

    Time frame: 12 months

    Percent responders; i.e. percent of subjects losing at least 10% TBW

  2. Excess Weight Loss Measures

    Time frame: 12 months

    Excess weight loss (EWL)

  3. Absolute Weight Loss Measures

    Time frame: 12 months

    Absolute weight loss

  4. BMI - Weight Loss Measures

    Time frame: 12 months

    Change in BMI

  5. Fasting Glucose

    Time frame: 12 months

    Mean change in fasting glucose

  6. Hemoglobin A1c

    Time frame: 12 months

    Mean change in Hemoglobin A1c

  7. Diabetes Remission and/or Improvements

    Time frame: 12 months

    Proportion of subjects experiencing diabetes remission and/or improvements

  8. Diabetes Medication Dosage and Frequency Changes

    Time frame: 12 months

    Mean change in the dosage and frequency of diabetes medications from baseline

  9. Serum Lipids

    Time frame: 12 months

    Mean change in serum lipids

  10. Blood Pressure Changes

    Time frame: 12 months

    Mean percent change in systolic/diastolic blood pressure

  11. Liver Changes using Fibroscan

    Time frame: 12 months

    Change in Controlled Attenuation Parameter (CAP) Scores from baseline

  12. Nutritional Status

    Time frame: 12 months

    Nutritional Status: changes in pre-albumin levels

  13. Albumin - Nutritional Status

    Time frame: 12 months

    Nutritional Status: changes in albumin levels

Sponsors and collaborators

Lead sponsor

GI Windows, Inc.

Industry

Registry information

Official study title

A Trial for a Procedure for Duodenal-Ileal Diversion With a Sleeve Gastrectomy for Patients With Obesity and Type 2 Diabetes Mellitus

Important dates

Study start
2021
Primary completion
2024
Study completion
2025
First posted
Nov 13, 2020
Registry last updated
Nov 20, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.